Develops drugs for cancer and neurodegenerative diseases.
Jun 2026Revenue $317M/yrExpenses $335M/yr
No trendCash runway ≈ 2.7 years from Jun 2026
Figures by year
When will Arvinas be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $317M and expenses $335M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $263M | $381M | −$119M |
| Dec 2024 | $263M | $514M | −$250M |
| Dec 2023 | $78.5M | $480M | −$402M |
| Dec 2022 | $131M | $395M | −$263M |
| Dec 2021 | $53.6M | $242M | −$188M |
| Dec 2020 | $25.9M | $147M | −$121M |
| Dec 2019 | $43.0M | $94.5M | −$51.5M |
| Dec 2018 | $14.3M | $58.1M | −$43.8M |
| Dec 2017 | $7.58M | $32.3M | −$24.8M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.